{
    "nctId": "NCT05746325",
    "briefTitle": "Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast Cancer",
    "officialTitle": "Pilot Feasibility Study of Tumor Treating Fields in Treatment of Leptomeningeal Metastases From Breast Carcinoma Involving the Spine",
    "overallStatus": "RECRUITING",
    "conditions": "Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Leptomeninges",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 5,
    "primaryOutcomeMeasure": "Incidence of significant toxicity of tumor treating fields (TTFs)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \\>= 18\n* Prior tissue diagnosis of breast cancer\n* Confirmed diagnosis of leptomeningeal metastases (LM) with positive cerebrospinal fluid (CSF) cytology for malignancy and meningeal enhancement (type 1A, 1B, and 1C)\n* Radiographic evidence on MRI of leptomeningeal enhancement within the cervical, thoracic or lumbar spine on spinal MRI\n* Life expectancy of at least 6 weeks\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, 2, or 3\n* Recovery from any neurotoxic effects of prior therapy\n* Platelet count greater than 25,000/mm\\^3, and absolute neutrophil count (ANC) greater than 0.5 mm\\^3\n* Patients must have adequate liver function, total bilirubin \\< 2.5 mg%, unless elevated total bilirubin is due to elevated indirect bilirubin from known Gilbert's disease, aspartate aminotransferase (AST) =\\< 3.5 times upper limits of normal; adequate renal function (calculated estimated glomerular filtration rate \\[eGFR\\] \\>= 30%)\n* Patients or legal medical representative must provide written informed consent\n* Patients must have suitable body habitus for placement of transducer arrays\n* Patients must be willing to wear the device for at least 18 hours a day (averaged over monthly)\n* Patients must be willing to return for the scheduled evaluations and perform the required assessments\n* Patients are without other disease or situation which would significantly compromise adequate assessment of safety and feasibility of the TTF\n* Patient willing to start a study treatment with TTF =\\< 14 days from registration\n\nExclusion Criteria:\n\n* Concomitant therapy:\n\n  * Must not be receiving concurrent high-dose methotrexate (\\>= 3 g/m\\^2), high dose thiotepa, or high-dose cytarabine (\\>= 3 g/m\\^2). Any other systemic chemotherapy, targeted treatment, hormonal or immunotherapy directed at the primary systemic malignancy is permitted\n  * Must not have received radiation therapy (RT) to the brain or spinal cord within 2 weeks of initiation of TTF\n  * Must be at least 1 week from cessation of any prior intrathecal chemotherapy\n* Women of childbearing age who are pregnant or lactating. (Male and female patients who are fertile must be willing to use an effective means of birth control to avoid pregnancy)\n* Patients with uncontrolled or untreated infection including active hepatitis, and human immunodeficiency virus (HIV)\n* Patients receiving any other investigational agents and must not have received any other investigational agent within 14 days prior to registration. The 14-day period should be extended if the investigational agent is known to have delayed toxicity\n* Patients known to be allergic to the hydrophilic gel utilized for transducer attachment\n* Patients with surgical hardware within the planned area of treatment in the spine (e.g., titanium rods, screws, fixation devices)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}